Endometrial Intraepithelial Neoplasia Clinical Correlates and Outcomes by Semere, Luwam G. et al.
Endometrial Intraepithelial Neoplasia
Clinical Correlates and Outcomes
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Semere, Luwam G., Emily Ko, Natasha R. Johnson, Allison F.
Vitonis, Laura J. Phang, Daniel W. Cramer, and George L. Mutter.
2011. “Endometrial Intraepithelial Neoplasia Clinical Correlates
and Outcomes.” Obstetrics & Gynecology 118 (1) (July): 21–28.
doi:10.1097/aog.0b013e31821d78af.
Published Version doi:10.1097/AOG.0b013e31821d78af
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27332627
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Endometrial Intraepithelial Neoplasia Clinical Correlates and
Outcomes
Luwam G. Semere, MD1, Emily Ko, MD1, Natasha R. Johnson, MD1, Allison F. Vitonis, SM1,
Laura J. Phang, MD1, Daniel W. Cramer, MD1, and George L. Mutter, MD2
1Department of Obstetrics and Gynecology, Brigham and Women’s Hospital Boston,
Massachusetts. USA.
2Department of Pathology, Brigham and Women’s Hospital. Boston, Massachusetts. USA.
Abstract
Objective—To estimate cancer outcome and outcome predictors of women with endometrial
intraepithelial neoplasia (EIN).
Methods—Outcomes of women with first diagnosis of EIN (“index biopsy”) was determined by
follow-up pathology. Patient characteristics were correlated with EIN regression, EIN persistence,
and progression to cancer.
Results—Fifteen percent (9.8-20.8%, 26/177) of index EIN biopsies had concurrent cancer. Of
the women with cancer-free index EIN biopsies, and follow-up by hysterectomy or more than 18
months surveillance, 25% (18.4-33.3%, 36/142) showed regression, 35% (27.4-43.7%, 50/142)
persistence, and 39% (31.3-48.0%, 56/142) progression. Non-white ethnicity and progestin
treatment reduced cancer outcomes (OR 0.16 (0.03,0.84) and 0.24 (0.08, 0.70) respectively), while
body mass index (BMI) greater than 25 increased malignant outcomes (BMI 25 or higher, OR
3.05 (1.10,8.45)).
Conclusion—EIN confers a high risk of cancer, but individual patient outcomes cannot be
predicted. Management should include exclusion of concurrent carcinoma and consideration of
hysterectomy.
Introduction
Endometrial cancer is the most common gynecologic malignancy in the United States with
an estimated 40,100 new cases diagnosed annually and 7,470 deaths occurring each year(1).
The histopathologic diagnosis of premalignant lesions of endometrioid endometrial cancer
has been a source of dispute among pathologists(2). The four-classes of World Health
Organization endometrial hyperplasia do not correspond to separate biologic entities, fail to
incorporate diagnostic advances achieved in the last 15 years(3), and are poorly
reproducible. The alternative EIN schema is a 2-class functionally defined (”benign
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endometrial hyperplasia”, a hormonal effect; and “EIN” a premalignant lesion) diagnostic
system which introduced several newly discovered histologic criteria associated with
heightened cancer risk such as minimum lesion size, precise extent of gland crowding, and
an internal comparison standard (background vs lesion) for interpretation of significant
cytologic change(4). This has proven to be a better predictor of disease progression and
equally important, is better able to determine which lesions are likely to remain benign(5).
There is no fixed concordance between WHO hyperplasia and EIN schema diagnoses
because of differing diagnostic criteria(6).
EIN diagnostic practices have only recently been deployed in routine clinical environments
(2001, at our institution) and as a result little has been published regarding care of patients
with EIN. The objective of this study was to estimate endometrial cancer outcomes among a
series of sequentially diagnosed women with EIN in a tertiary care multi-group practice. In
addition, we sought to estimate if there were patient demographic, clinical, or treatment
modality characteristics which influenced the outcomes of EIN involution to a benign
histology, compared to persistence, or progression to endometrial cancer.
Materials and Methods
This study received approval from the Partners Human Research Committee, the
institutional review board for Brigham and Women’s Hospital (BWH). From June 2002
until July 2006, patients receiving a diagnosis of Endometrial Intraepithelial Neoplasia
(EIN) upon endometrial sampling at Brigham and Women’s Hospital and its community
affiliates were identified through pathology record review. This sample included patients
from the gynecology resident continuity practice, faculty clinics, gynecologic oncology
clinics, and community health centers and satellite practices. Medical records were obtained
from the Partners Health Care electronic medical record system and from paper charts.
Demographic data, obstetric history, gynecologic history, medical history, surgical history,
operative information, and pathology results were collected from this medical record review.
Inclusion in the study was based on a first pathologic report diagnosis of EIN within an
endometrial sample (biopsy or curetting, designated here as an “index biopsy”). Women
with previous EIN diagnoses, or endometrial carcinoma, were excluded, as were those in
whom the index biopsy histological sections were unavailable for review. The routine
pathology interpretations were reported by eleven pathologists at BWH who randomly
encountered the specimens as part of rotating service coverage. Diagnosis of EIN required
the following: 1) glandular volume exceeding that of stroma; 2) cytological demarcation
from surrounding normal glands; 3) lesions with largest diameter greater than 1mm; 4)
exclusion of confounding benign processes such as degenerative or hormonal effects; and 5)
exclusion of carcinoma(8).
Glass histological sections of the index biopsies were re-reviewed by a single pathologist
(GLM), for presence or absence of EIN, and presence or absence of concurrent carcinoma in
the same specimen. Since management was based on the pathology report diagnosis, we did
not exclude those patients in whom the diagnosis of EIN was not upheld upon re-evaluation
of available slides. Follow-up endometrial pathology specimens (obtained after the index
EIN biopsy date) varied in number and format (biopsy, curetting, hysterectomy) between
patients. Follow-up endometrial specimen pathology reports were reviewed and the outcome
censored at first occurrence of carcinoma or last pathology specimen diagnosis. Some
women received progestin treatment after initial EIN diagnosis, and these were recorded for
analysis.
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A retrospective cohort was constructed from those women with cancer-free EIN at initial
diagnosis to estimate endometrial cancer outcomes over time. Kaplan-Meier survivor
analysis was used to determine the proportion of cancer-free patients during the available
follow-up period. Cancer outcomes were then compared for those women who were, or were
not, treated after diagnosis with progestins. Outcomes were categorized as cancer if any
single follow-up specimen had this diagnosis. For those that did not progress to carcinoma,
the outcome was based upon pathology seen in the last available endometrial pathology
specimen.
A case-control analysis was then conducted comparing clinical characteristics of women
whose EIN regressed (controls) to two separate case groups: women with persistence of EIN
on subsequent sampling or hysterectomy and women with a diagnosis of cancer, either in the
index biopsy or during follow-up. All controls had either definitive hysterectomy or more
than eighteen months of follow-up, to accurately reflect clinical practice outcomes.
Categorical variables were compared using chi-square and Fisher’s exact test and continuous
variables were compared using t-tests. Logistic regression analysis was used to calculate age
adjusted odds ratios . Statistical significance was defined as P<0.05. SAS statistical analysis
software (version 9.1, SAS Institute, Cary, NC) was used to perform all analyses.
Results
177 new cases of EIN were identified by endometrial sampling from January 2002 through
July 2006. All H&E slides were reviewed by a single pathologist, GLM, with a diagnosis of
EIN confirmed in 94% of the cases. Patients averaged 53 years of age with a median of 53
and ranged from 26 to 94. Self-reported ethnicity was available for 103 patients. Of these,
81 (78.6% (69.4%-86.1%)) were Caucasian, 8 (7.8% (3.4-14.7%)) were Hispanic, 10 (9.7%
(4.7-17.1%)) were African-American, and 4 (3.9% (1.1-9.6%)) were Asian. Figure 1
demonstrates the outcomes of all patients in the study. In 11.9% (7.5-17.6%, 21/177) of
cases we had no information regarding follow-up endometrial sampling or hysterectomy,
one of which had a concurrent carcinoma in the index biopsy. 82.7% (75.8-88.3%, 129/156)
of cases with follow-up eventually had a hysterectomy, of which the majority (70.5%
(61.9-78.2%), 91/129) were within 3 months of the index biopsy. 17.3% (11.7-24.2%,
27/156) with available follow-up only had biopsies.
Overall cancer incidence was 35.7% (28.2-43.7%, 56/157), diagnosed at various stages of
patient management. First diagnosis of carcinoma was most common within the initial EIN-
bearing biopsy (26 cases), but others occurred during follow-up biopsy sampling (8 cases),
or at definitive hysterectomy (22 cases). Patients with EIN who remained cancer-free during
follow-up (102 cases) demonstrated equal frequencies of EIN persistence 50% (40.0-60.1%)
(51/102) and “regression” to a benign histology (51/102).
All (56/56) of the endometrial cancers were of the endometrioid (Type I) type. Most (85%
(72.9-93.4%), 46/54) were well differentiated, whereas 11% (4.2-22.6%, 6/54) were
moderately differentiated, and 4% (0.4-12.7%, 2/54) were poorly differentiated. Grading of
two cases was unavailable from the pathology report. 28% (16.4-41.6%, 15/54) of cancers
invaded the myometrium, confined to the inner half of the myometrial thickness in 87%
(59.5-98.3%) of (13/15) cases. All cases with lymph node sampling (8/8, 63.1%-100%) had
cancer free nodes, and only one (1/54, 0.05-9.9%) had myometrial lymphovascular invasion.
There were two cases of disease spread beyond the uterine corpus, one metastasis to the
ovarian surface and one with local extension to the endocervical stroma.
21% (15.0-28.6%, 32/151) of the women in our study were treated medically with
progestins (excluding 26 with unknown treatment status), all were cancer-free in the index
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biopsy. Cancer outcomes were not significantly different in women treated (22%
(9.3-40.0%), 7/32) compared to not treated (39% (30.6-48.9%), 47/119) with progesterone
(p=0.095). Women receiving medical therapy by progesterone were significantly younger
than those not receiving progesterone (mean age 48.4 versus 54.0 years, P = .012), and were
significantly less likely to be parous than women not receiving progesterone therapy (43.3%
(25.5-62.6%, 13/30) versus 69.6% (60.3-77.8%, 80/115), P=.01). Amongst women who
remained cancer free, the rate of EIN involution as seen by reversion to a benign histology
was significantly greater in women treated with progesterone compared to untreated (81%
(54.4-96.0%), 13/16 versus 32% (20.6-44.7%), 20/63; p=0.005).
The retrospective cohort analysis was based on 131 patients with a diagnosis of EIN only on
initial sampling, and available follow-up. These were variably managed by immediate
hysterectomy (60% (51.4-68.7%), 79/131), biopsy surveillance only (20% (13.4-27.7%),
26/131), or biopsy surveillance followed by hysterectomy (20% (13.4-27.7%), 26/131). The
pathology outcomes of all 131 patients were 23% (16.0-31.0%, 30/131) endometrial cancer,
39% (30.5-47.8%, 51/131) persistent EIN, and 38% (29.8-47.1%, 50/131) benign pathology.
Figure 2 demonstrates the proportion of cancer-free patients during the follow-up period
(median 74 days, mean 269 days, and SD 462 days). Interval from index biopsy with EIN to
diagnosis of cancer had a median of 56 days (Mean 152 days, and SD 231 days. Of the 30
women who progressed to cancer, 83% (65.3-94.4%, 25/30) were diagnosed within one year
and 17% (5.6-34.7%, 5/30) after one year.
For the case-control analysis, women who did not undergo definitive hysterectomy or who
had less than eighteen months of follow-up (n=35) were excluded, leaving a total of 142
cases and controls. Demographic variables including age (p=0.09), ethnicity (p=0.19),
marital status (p=0.51), insurance status (p=0.10), and indications for initial endometrial
sampling (p=0.15) appeared to be similar (Fishers exact) between those with follow-up and
those without (Table 5, available online at http://links.lww.com/xxx). For those women with
adequate followup, demographic, clinical, and reproductive characteristics of women with
involuted EIN (controls, n=36, 25% (18.4-33.3%, 36/142) were compared to those women
with EIN persistence (cases, n=50, 35% (27.4-43.7%, 50/142) or EIN progression
(concurrent or future cancer, cases, n=56, 39% (31.3-48.0%, 56/142).
Table 1 demonstrates the demographic characteristics of the patients in relation to their
outcome diagnosis. Women who had benign pathology did not differ significantly in regards
to age, marital status, or insurance status from persistent EIN or cancer cases. Significantly
fewer women who had a diagnosis of cancer were of non-white ethnicity (OR 0.16, 95% CI
0.03-0.84). “Other” indications for initial biopsy include endometrial cells on pap (8);
atypical cells on pap (1); thickened endometrial lining on ultrasound (5); endometrial lesion
on imaging (2); evaluation for infertility (2); polyps seen on hysterosalpingogram during
evaluation for infertility (1); Lynch syndrome (1); tamoxifen use (1); history of hyperplasia
on hormone replacement therapy (1).
Clinical variables are shown in Table 2 for each outcome group. Diabetes, hypertension,
smoking status, alcohol use, family history of any type of malignancy, and personal history
of any prior non-endometrial malignancy did not differ significantly. Body mass index ≥ 25
was significantly associated with increased cancer outcomes (OR 3.05, 95% CI 1.10-8.45).
Table 3 compares reproductive history between cases and controls with no significant
differences found between the three groups for gravidity, parity, prior tubal ligation,
postmenopausal status, postmenopausal bleeding, irregular (premenopausal) menses,
polycystic ovarian syndrome diagnosis, ovarian cysts requiring surgery, prior IUD use, and
EIN presentation during infertility workup. Amongst four women pursuing infertility
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treatment at the time of EIN diagnosis, one had EIN involution and three had cancer
outcomes (OR 2.81, 95% CI 0.25-31.5).
Exogenous hormone use is illustrated in Table 4. Use of oral contraceptives, hormone
replacement therapy, tamoxifen, and progestin for any indication did not differ significantly
between patients with benign outcomes when compared to those with EIN persistence or
progression to carcinoma. Progestin use specifically for the treatment of EIN did result in a
decreased risk of EIN persistence (OR 0.11, 95% CI 0.03-0.42) and progression (OR 0.24,
95% CI 0.08-0.70).
Discussion
Diagnostic classification of premalignant endometrial lesions is now in a state of transition
from the legacy 4-class WHO 1994 hyperplasia schema (hyperplasia with or without atypia,
complex or simple architecture) to a 2-class EIN schema (benign endometrial hyperplasia/
EIN)(8). Advantages of the EIN system are better defined histopathologic diagnostic
criteria, superior clinical outcome prediction, and lucid communication for each diagnosis of
the disease process (hormonal/premalignant)(4;7). By entering all sequential patients with a
first diagnosis of EIN within a defined practice environment, we have minimized case
selection bias and are able to generate a practitioner’s view of current management
practices, clinical outcomes, and demographics of affected patients using the EIN diagnostic
approach. Pathologic diagnosis of EIN was highly consistent amongst pathologists, with the
initial diagnoses (made by a pool of 11 surgical pathologists) confirmed upon central review
in 94% of cases.
EIN is a high risk factor for malignancy, with 35.7% (28.2-43.7%, 56/157) overall having or
developing carcinoma. Among women diagnosed with EIN, 15% (9.8-20.8%, 26/177) had
concurrent cancer in the presenting biopsy, 19% (12.7-26.9%, 25/131) developed cancer
within one year, and an additional 4% (1.2-8.7%, 5/131) after one year. This compares to a
37.8% (56/148) synchronous cancer rate in women with EIN undergoing immediate
hysterectomy (9), and a 41% cancer rate during one year of clinical follow-up (7). Prior
estimates of concurrent endometrial cancer at the time of diagnosis of atypical endometrial
hyperplasia are similar, at 43% for immediate hysterectomy(10). Short follow-up interval in
our series precluded estimates of additional longer term progression events to carcinoma, but
other studies have shown that cancer occurrences beyond 1 year of EIN diagnosis are 45
times more likely than EIN free women, occurring in 18% of patients at a median interval of
4 years (average 4.1 years)(7). Although we have used the term cancer “progression”
throughout for cancers diagnosed after the initial EIN bearing biopsy, some unknown
proportion of these represent occult carcinomas present in the patient, but missed by biopsy,
at the time of initial EIN diagnosis.
Our case control analysis showed that overweight and obese women with EIN (body mass
index ≥25) were at 3.05 fold increased risk for development of endometrial cancer
compared to non-obese patients with EIN. This is consistent with prior epidemiologic data
in which obesity is a risk factor for endometrial carcinoma, perhaps mediated by changes in
endogenous steroid hormone metabolism (11;12). We did not have sufficient numbers of
morbidly obese (BMI>38) patients to determine whether the risk effect is proportionately
scaled across the full range of body weights, or is a discrete threshold effect.
Progestin treatment of EIN, most common in younger nulliparous patients desiring to
maintain fertility, was utilized in 21% (15.0-28.6%, 32/151) of our study population and
associated with decreased risk for EIN persistence (OR 0.11), or progression to carcinoma
(OR 0.24). This coincides with a developing experience showing that progestin therapy may
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in some cases be effective in nonsurgical treatment of endometrial precancers(13;14) or
even carcinoma(15). In general, however, accurate estimates of efficacy are severely limited
by lack of standardization of therapeutic regimen (agent, dosage, and administration
schedule) in addition to uncertainty of the best outcome measures (number of biopsies,
surveillance duration, and validity of on-agent samples). Long term failures require more
protracted clinical follow-up than generally available, and there are limitations to pathologic
interpretation of residual disease in an endometrial sample obtained under the influence of
active progestational therapy which dramatically alters lesion cytology and
architecture(15;16). Thus, some of the “benign” outcomes may be occult EIN persistence
missed by the pathologist, and others a transient shrinkage of EIN lesions, rather than long
term cure. Our own study is constrained by thesefactors, and best interpreted as evidence of
a short term therapeutic response rather than permanent “cure”. More studies, preferably
with multiple surveillance biopsies following completion of progestin therapy, need to be
done to determine the long term natural history of these patients.
Endometrioid carcinoma and EIN have a common pathogenesis, and thus share many
overlapping risk factors that require large numbers of patients to resolve separately. Our
study sample size may have limited our power to detect risk factors specific to the EIN
patient which predict cancer outcomes. Furthermore, human studies constraints in this
retrospective context prohibited contacting patients and thus we were unable to utilize
standardized exposure questionnaires.
All cancer outcomes seen in our study were of an endometrioid histologic type, usually well
differentiated, with superficial or no myometrial invasion. However, there were two patients
with greater than 50% myometrial invasion, and another two patients with evidence of
disease beyond the uterine corpus. Careful clinical evaluation of the possibility of concurrent
carcinoma is advised in all new diagnoses of EIN. In those cases where surgical
management is the treatment chosen, examination of the hysterectomy specimen will
perform this function.
Our experience with EIN is that it is a reproducible and specific diagnosis that allows us to
identify those premalignant endometrial lesions that place a patient at risk for carcinoma.
Management of EIN lesions should consider the heightened cancer risk that diagnosis
confers, and generally follow those guidelines previously established for atypical
endometrial hyperplasia. Given the high likelihood of concurrent malignancy, women
identified as having EIN lesions warrant close follow-up and consideration of treatment with
hysterectomy. Younger women wishing to retain fertility are in some cases being managed
with progestin therapy and we did find this may promote involution of EIN to a benign
histology and reduce the progression likelihood to carcinoma. Despite these promising data,
lack of therapeutic standardization, defined endpoints, and prospective blinded measures of
treatment efficacy are limitations to assessment of the risks and benefits of this approach.
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Figure 1.
Flowchart of study participants.
Clinical management and clinical outcomes of 177 incident EIN cases. Bracketed numbers
show total cases in each node.
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Figure 2.
Progression from EIN to Carcinoma.
Kaplan Meyer (“survival”) curve showing proportion (Y axis) of patients with incident EIN
remaining cancer free during follow-up (X axis). Gray lines are 95% confidence intervals.
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Table 5
Patients Included in the Outcome Follow-Up (Greater Than or Equal to 18 Months) Analyses Compared to All
Excluded Due to Inadequate (Less Than 18 Months) Follow-Up
Benigns+EIN+Cancers
Included in Analysis
(n=142)
Benigns+EIN
Excluded
(n=35)
Fisher’s Exact
P-value
Age
 <49 43 (30.3) 15 (42.9) 0.09
 49-55 51 (35.9) 6 (17.1)
 >55 48 (33.8) 14 (40.0)
 Mean (standard error) 52.8 (9.8) 53.8 (16.5) 0.71
Ethnicity
 White 70 (81.4) 11 (64.7) 0.19
 Non-white 16 (18.6) 6 (35.3)
Marital status
 Single 46 (33.3) 11 (40.7) 0.51
 Married 92 (66.7) 16 (59.3)
Insurance status
 Free care/Medicaid 20 (14.5) 8 (27.6) 0.10
 Private 118 (85.5) 21 (72.4)
Indication for initial
endometrial sampling
Postmenopausal bleeding 59 (43.1) 18 (58.1) 0.15
 Heavy bleeding 29 (21.2) 4 (12.9)
 Irregular bleeding 27 (19.7) 2 (6.4)
 Other 22 (16.1) 7 (22.6)
EIN, endometrial intraepithelial neoplasia.
Obstet Gynecol. Author manuscript; available in PMC 2012 July 1.
